Multi-omics analysis defines 5-fluorouracil drug resistance in 3D HeLa carcinoma cell model

Abstract

Cervical cancer is a serious health problem in women around the globe. However, the use of clinical drug is seriously dampened by the development of drug resistance. Efficient in vitro tumor model is essential to improve the efficiency of drug screening and the accuracy of clinical application. Multicellular tumor spheroids (MTSs) can in a way recapitulates tumor traits in vivo, thereby representing a powerful transitional model between 2D monolayer culture and xenograft. In this study, based on the liquid overlay method, a protocol for rapid generation of the MTSs with uniform size and high reproducibility in a high-throughput manner was established. As expected, the cytotoxicity results showed that there was enhanced 5-fluorouracil (5-FU) resistance of HeLa carcinoma cells in 3D MTSs than 2D monolayer culture with a resistance index of 5.72. In order to obtain a holistic view of the molecular mechanisms that drive 5-FU resistance in 3D HeLa carcinoma cells, a multi-omics study was applied to discover hidden biological regularities. It was observed that in the 3D MTSs mitochondrial function-related proteins and the metabolites of the tricarboxylic acid cycle (TCA cycle) were significantly decreased, and the cellular metabolism was shifted towards glycolysis. The differences in the protein synthesis, processing, and transportation between 2D monolayer cultures and 3D MTSs were significant, mainly in the heat shock protein family, with the up-regulation of protein folding function in endoplasmic reticulum (ER), which promoted the maintenance of ER homeostasis in the 3D MTSs. In addition, at the transcript and protein level, the expression of extracellular matrix (ECM) proteins (e.g., laminin and collagen) were up-regulated in the 3D MTSs, which enhanced the physical barrier of drug penetration. Summarizing, this study formulates a rapid, scalable and reproducible in vitro model of 3D MTS for drug screening purposes, and the findings establish a critical role of glycolytic metabolism, ER hemostasis and ECM proteins expression profiling in tumor chemoresistance of HeLa carcinoma cells towards 5-FU.

Keywords

Drug resistance mechanism / HeLa carcinoma cells / Multicellular tumor spheroid / Multi-omics analysis / Preclinical evaluation / Tumor metabolism

References

[1] Aird KM, Zhang R. Nucleotide metabolism, oncogene-induced senescence and cancer. Cancer Lett, 2015, 356(2): 204-210.

[2] Anggayasti WL, Imashiro C, Kuribara T, Totani K, Takemura K. Low-frequency mechanical vibration induces apoptosis of A431 epidermoid carcinoma cells. Eng Life Sci, 2020, 20(7): 232-238.

[3] Apicella M, Giannoni E, Fiore S, Ferrari KJ, Fernández-Pérez D, Isella C, Corso S. Increased lactate secretion by cancer cells sustains non-cell-autonomous adaptive resistance to MET and EGFR Targeted Therapies. Cell Metab, 2018, 28(6): 848-865.

[4] Baltes F, Pfeifer V, Silbermann K, Caspers J, Wantoch von Rekowski K, Schlesinger M, Bendas G. beta1-Integrin binding to collagen type 1 transmits breast cancer cells into chemoresistance by activating ABC efflux transporters. Biochim Biophys Acta Mol Cell Res, 2020, 1867(5): 118663.

[5] Benton G, Arnaoutova I, George J, Kleinman HK, Koblinski J. Matrigel: from discovery and ECM mimicry to assays and models for cancer research. Adv Drug Deliv Rev, 2014, 79–80: 3-18.

[6] Brown MJ, Bahsoun S, Morris MA, Akam AEC. Determining conditions for successful culture of multi-cellular 3d tumour spheroids to investigate the effect of mesenchymal stem cells on breast cancer cell invasiveness. Bioengineering (basel), 2019, 6(4): 101-117.

[7] Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer, 2011, 11(2): 85-95.

[8] Caron E, Ghosh S, Matsuoka Y, Ashton-Beaucage D, Therrien M, Lemieux S, Kitano H. A comprehensive map of the mTOR signaling network. Mol Syst Biol, 2010, 6: 453.

[9] Cascone T, McKenzie JA, Mbofung RM, Punt S, Wang Z, Xu C, Peng W. Increased tumor glycolysis characterizes immune resistance to adoptive T Cell Therapy. Cell Metab, 2018, 27(5): 977-987.

[10] Costa EC, de Melo-Diogo D, Moreira AF, Carvalho MP, Correia IJ. Spheroids formation on non-adhesive surfaces by liquid overlay technique: considerations and practical approaches. Biotechnol J, 2018, 13(1): 1700417.

[11] Denko, & Nicholas, C. . Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer, 2008, 8(9): 705-713.

[12] Dittmer J, Leyh B. The impact of tumor stroma on drug response in breast cancer. Semin Cancer Biol, 2015, 31(14): 3-15.

[13] Dominijanni A, Devarasetty M, Soker S. Manipulating the tumor microenvironment in tumor organoids induces phenotypic changes and chemoresistance. iScience, 2020, 23(12): 101851.

[14] Donner DB, Nakakura EK, Venook AP, Lenz HJ, Zhang W, Hwang J, Warren RS. High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma. PLoS ONE, 2019, 14(7

[15] Fan J, Kamphorst JJ, Mathew R, Chung MK, White E, Shlomi T, Rabinowitz JD. Glutamine-driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia. Mol Syst Biol, 2013, 9: 712.

[16] Frezza C. The role of mitochondria in the oncogenic signal transduction. Int J Biochem Cell Biol, 2014, 48: 11-17.

[17] Fuxe J, Karlsson MC. TGF-beta-induced epithelial-mesenchymal transition: a link between cancer and inflammation. Semin Cancer Biol, 2012, 22(5–6): 455-461.

[18] Gaude E (2018) Mitochondrial metabolism in cancer transformation and progression. (Doctor of Philosophy Doctoral Thesis), University of Cambridge, Cambridge, UK. https://www.rioxx.net/licenses/all-rights-reserved/

[19] Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Coudert B. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil–leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol, 2000, 18(1): 136-136.

[20] Gomez KE, Wu F, Keysar SB, Morton JJ, Miller B, Chimed TS, Jimeno A. Cancer Cell CD44 mediates macrophage/monocyte-driven regulation of head and neck cancer stem cells. Cancer Res, 2020, 80(19): 4185-4198.

[21] Gu S, Tan J, Li Q, Liu S, Ma J, Zheng Y, Li X. Downregulation of LAPTM4B Contributes to the Impairment of the Autophagic Flux via Unopposed Activation of mTORC1 Signaling During Myocardial Ischemia/Reperfusion Injury. Circul Res, 2020, 127(7): 148-165.

[22] Guang MHZ, McCann A, Bianchi G, Zhang L, Dowling P, Bazou D, Anderson KC. Overcoming multiple myeloma drug resistance in the era of cancer 'omics'. Leuk Lymphoma, 2018, 59(3): 542-561.

[23] Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Mansfield KD, Schumacker PT. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab, 2005, 1(6): 401-408.

[24] Hensley CT, Faubert B, Yuan Q, Lev-Cohain N, Jin E, Kim J, DeBerardinis RJ. Metabolic heterogeneity in human lung tumors. Cell, 2016, 164(4): 681-694.

[25] Herst PM, Tan AS, Scarlett DJ, Berridge MV. Cell surface oxygen consumption by mitochondrial gene knockout cells. Biochim Biophys Acta, 2004, 1656(2–3): 79-87.

[26] Hickman, J. A., Graeser, R., de Hoogt, R., Vidic, S., Brito, C., Gutekunst, M., Consortium, I. P. Three-dimensional models of cancer for pharmacology and cancer cell biology: capturing tumor complexity in vitro/ex vivo. Biotechnol J, 2014, 9(9): 1115-1128.

[27] Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA. Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol, 2010, 148(1): 3-15.

[28] Hodkinson PS, Mackinnon AC, Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Int J Radiat Biol, 2007, 83(11–12): 733-741.

[29] Hoyer-Hansen M, Jaattela M. Connecting endoplasmic reticulum stress to autophagy by unfolded protein response and calcium. Cell Death Differ, 2007, 14(9): 1576-1582.

[30] Hutmacher DW. Biomaterials offer cancer research the third dimension. Nat Mater, 2010, 9(2): 90-93.

[31] Ijichi K, Adachi M, Ogawa T, Hasegawa Y, Murakami S. Cell-cycle distribution and Thymidylate Synthase (TS) expression correlate with 5-FU resistance in head and neck carcinoma cells. Anticancer Res, 2014, 34(6): 2907-2911.

[32] Inch WR, Mccredie JA, Sutherland RM. Growth of nodular carcinomas in rodents compared with multi-cell spheroids in tissue culture. Growth, 1970, 34(3): 271.

[33] Jarosz D. Hsp90: a global regulator of the genotype-to-phenotype map in cancers. Adv Cancer Res, 2016, 129: 225-247.

[34] Jiang K, Liang L, Lim CT. Engineering confining microenvironment for studying cancer metastasis. Science, 2021, 24(2): 102098.

[35] Joyce MH, Lu C, James ER, Hegab R, Allen SC, Suggs LJ, Brock A. Phenotypic basis for matrix stiffness-dependent chemoresistance of breast cancer cells to doxorubicin. Front Oncol, 2018, 8: 337.

[36] Kalfe A, Telfah A, Lambert J, Hergenroder R. Looking into living cell systems: planar waveguide microfluidic nmr detector for in vitro metabolomics of tumor spheroids. Anal Chem, 2015, 87(14): 7402-7410.

[37] Keshavarz-Fathi M, Rezaei N. Cancer immunoprevention: current status and future directions. Arch Immunol Ther Exp, 2021, 69(1): 3-22.

[38] Klein S, Heinzle E. Isotope labeling experiments in metabolomics and fluxomics. Wiley Interdiscip Rev: Syst Biol Med, 2012, 4(3): 261-272.

[39] Koudan EV, Gryadunova AA, Karalkin PA, Korneva JV, Meteleva NY, Babichenko II, Bulanova EA. Multiparametric analysis of tissue spheroids fabricated from different types of cells. Biotechnol J, 2020, 15(5): e1900217.

[40] Langhans SA. Three-dimensional in vitro cell culture models in drug discovery and drug repositioning. Front Pharmacol, 2018, 9: 6-20.

[41] Lauschke VM, Shafagh RZ, Hendriks DFG, Ingelman-Sundberg M. 3D primary hepatocyte culture systems for analyses of liver diseases, drug metabolism, and toxicity: emerging culture paradigms and applications. Biotechnol J, 2019, 14(7

[42] Lee DC, Sohn HA, Park ZY, Oh S, Kang YK, Lee KM, Yeom YI. A lactate-induced response to hypoxia. Cell, 2015, 161(3): 595-609.

[43] Li X, Zhang N, Ye H, Song P, Chang W, Chen L, Wang N. HYOU1 promotes cell growth and metastasis via activating PI3K/AKT signaling in epithelial ovarian cancer and predicts poor prognosis. Eur Rev Med Pharmacol Sci, 2019, 23(10): 4126-4135.

[44] Locasale JW. Metabolic rewiring drives resistance to targeted cancer therapy. Mol Syst Biol, 2012, 8: 597.

[45] Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer, 2003, 3(5): 330-338.

[46] Lu T, Bankhead A 3rd, Ljungman M, Neamati N. Multi-omics profiling reveals key signaling pathways in ovarian cancer controlled by STAT3. Theranostics, 2019, 9(19): 5478-5496.

[47] Magani F, Bray ER, Martinez MJ, Zhao N, Copello VA, Heidman L, Burnstein KL. Identification of an oncogenic network with prognostic and therapeutic value in prostate cancer. Mol Syst Biol, 2018, 14(8): 8202.

[48] Maier LJ, Kallenberger SM, Jechow K, Waschow M, Eils R, Conrad C. Unraveling mitotic protein networks by 3D multiplexed epitope drug screening. Mol Syst Biol, 2018, 14(8): 8238.

[49] Manzoni C, Kia DA, Vandrovcova J, Hardy J, Wood NW, Lewis PA, Ferrari R. Genome, transcriptome and proteome: the rise of omics data and their integration in biomedical sciences. Brief Bioinform, 2018, 19(2): 286-302.

[50] Martínez-Monge I, Albiol J, Lecina M, Liste-Calleja L, Miret J, Solà C, Cairó JJ. Metabolic flux balance analysis during lactate and glucose concomitant consumption in HEK293 cell cultures. Biotechnol Bioeng, 2018, 116(2): 388-404.

[51] Mischiati C, Ura B, Roncoroni L, Elli L, Cervellati C, Squerzanti M, Agostinelli E. Changes in protein expression in two cholangiocarcinoma cell lines undergoing formation of multicellular tumor spheroids in vitro. PLoS ONE, 2015, 10(3

[52] Mohamed FEA, Khalil EZI, Toni NDM. Caveolin-1 Expression Together with VEGF can be a predictor for lung metastasis and poor prognosis in osteosarcoma. Pathol Oncol Res, 2020, 26(3): 1787-1795.

[53] Mohanty A, Nam A, Pozhitkov A, Yang L, Srivastava S, Nathan A, Salgia R. A Non-genetic Mechanism Involving the Integrin beta4/Paxillin Axis Contributes to Chemoresistance in Lung Cancer. iScience, 2020, 23(9): 101496.

[54] Negarandeh R, Salehifar E, Saghafi F, Jalali H, Janbabaei G, Abdhaghighi MJ, Nosrati A. Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients. BMC Cancer, 2020, 20(1): 560.

[55] Nunes AS, Costa EC, Barros AS, de Melo-Diogo D, Correia IJ. Establishment of 2D cell cultures derived from 3D MCF-7 spheroids displaying a doxorubicin resistant profile. Biotechnol J, 2019, 14(4): e1800268.

[56] Oldham WM, Clish CB, Yang Y, Loscalzo J. Hypoxia-Mediated Increases in l -2-hydroxyglutarate Coordinate the Metabolic Response to Reductive Stress. Cell Metab, 2015, 22(2): 291-303.

[57] Orlando BJ, Liao M. ABCG2 transports anticancer drugs via a closed-to-open switch. Nat Commun, 2020, 11(1): 2264.

[58] Pavan Grandhi TS, Potta T, Nitiyanandan R, Deshpande I, Rege K. Chemomechanically engineered 3D organotypic platforms of bladder cancer dormancy and reactivation. Biomaterials, 2017, 142: 171-185.

[59] Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat, 2004, 7(2): 97-110.

[60] Perez-Tomas R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem, 2006, 13(16): 1859-1876.

[61] Renner K, Singer K, Koehl GE, Geissler EK, Peter K, Siska PJ, Kreutz M. Metabolic hallmarks of tumor and immune cells in the tumor microenvironment. Front Immunol, 2017, 8: 248.

[62] Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol, 2007, 8(7): 519-529.

[63] Ruprecht B, Zaal EA, Zecha J, Wu W, Berkers CR, Kuster B, Lemeer S. Lapatinib resistance in breast cancer cells is accompanied by phosphorylation-mediated reprogramming of glycolysis. Cancer Res, 2017, 77(8): 1842-1853.

[64] Santo VE, Rebelo SP, Estrada MF, Alves PM, Boghaert E, Brito C. Drug screening in 3D in vitro tumor models: overcoming current pitfalls of efficacy read-outs. Biotechnol J, 2017, 12(1): 1600505.

[65] Sarvestani SK, DeHaan RK, Miller PG, Bose S, Shen X, Shuler ML, Huang EH. A tissue engineering approach to metastatic colon cancer. iScience, 2020, 23(11): 101719.

[66] Schroll MM, LaBonia GJ, Ludwig KR, Hummon AB. Glucose restriction combined with autophagy inhibition and chemotherapy in HCT 116 spheroids decreases cell clonogenicity and viability regulated by tumor suppressor genes. J Proteome Res, 2017, 16(8): 3009-3018.

[67] Seker F, Cingoz A, Sur-Erdem I, Erguder N, Erkent A, Uyulur F, Bagci-Onder T. Identification of SERPINE1 as a regulator of glioblastoma cell dispersal with transcriptome profiling. Cancers, 2019, 11(11): 1651-1672.

[68] Sengupta R, Honey K. AACR Cancer Progress Report 2020: Turning Science into Lifesaving Care, 2020, New York: Clinical Cancer Research.

[69] Seyfried TN, Arismendi-Morillo G, Mukherjee P, Chinopoulos C. On the Origin of ATP Synthesis in Cancer. iScience, 2020, 23(11): 101761.

[70] Singh DK, Ku C-J, Wichaidit C, Steininger RJ III, Wu LF, Altschuler SJ. Patterns of basal signaling heterogeneity can distinguish cellular populations with different drug sensitivities. Mol Syst Biol, 2010

[71] Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, Kimmelman AC. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature, 2013, 496(7443): 101-105.

[72] Spinelli JB, Yoon H, Ringel AE, Jeanfavre S, Clish CB, Haigis MC. Metabolic recycling of ammonia via glutamate dehydrogenase supports breast cancer biomass. Science, 2017, 358(6365): 941-946.

[73] Stella GM, Benvenuti S, Comoglio PM. Targeting the MET oncogene in cancer and metastases. Expert Opin Investig Drugs, 2010, 19(11): 1381-1394.

[74] Tomasetti C, Li L, Vogelstein B. Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Science, 2017, 355(6331): 1330-1334.

[75] Valkenburg KC, de Groot AE, Pienta KJ. Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol, 2018, 15(6): 366-381.

[76] Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 2009, 324(5930): 1029-1033.

[77] Veenstra TD. Systems Biology and Multi-Omics. Proteomics, 2021, 21(3–4

[78] Wang T, Wang L, Wang G, Zhuang Y. Leveraging and manufacturing in vitro multicellular spheroid-based tumor cell model as a preclinical tool for translating dysregulated tumor metabolism into clinical targets and biomarkers. Bioresourc Bioprocess, 2020, 7(1): 1-34.

[79] Warren CFA, Wong-Brown MW, Bowden NA. BCL-2 family isoforms in apoptosis and cancer. Cell Death Dis, 2019, 10(3): 177.

[80] Wild C, Weiderpass E, Stewart B. World cancer report: cancer research for cancer prevention, 2020, Lyon: International Agency for Research on Cancer, 23-33.

[81] Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Huang P. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res, 2005, 65(2): 613-621.

[82] Yan C, Li TS. Dual Role of Mitophagy in Cancer Drug Resistance. Anticancer Res, 2018, 38(2): 617-621.

[83] Yang H, Zhou L, Shi Q, Zhao Y, Lin H, Zhang M, Ye D. SIRT3-dependent GOT2 acetylation status affects the malate-aspartate NADH shuttle activity and pancreatic tumor growth. EMBO J, 2015, 34(8): 1110-1125.

[84] Ye P, Xing H, Lou F, Wang K, Pan Q, Zhou X, Li D. Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription. Cancer Chemother Pharmacol, 2016, 77(3): 613-621.

[85] Yizhak K, Le Devedec SE, Rogkoti VM, Baenke F, de Boer VC, Frezza C, Ruppin E. A computational study of the Warburg effect identifies metabolic targets inhibiting cancer migration. Mol Syst Biol, 2014

[86] Yong C, Stewart GD, Frezza C. Oncometabolites in renal cancer. Nat Rev Nephrol, 2019, 16(3): 156-172.

[87] Yu L, Chen MC, Cheung KC. Droplet-based microfluidic system for multicellular tumor spheroid formation and anticancer drug testing. Lab Chip, 2010, 10(18): 2424-2432.

[88] Zhang Q, Huang R, Hu H, Yu L, Tang Q, Tao Y, Wang G. Integrative analysis of hypoxia-associated signature in pan-cancer. Science, 2020, 23(9): 101460.

[89] Zhu J, Thompson CB. Metabolic regulation of cell growth and proliferation. Nat Rev Mol Cell Biol, 2019, 20(7): 436-450.

[90] Zietarska M, Maugard CM, Filali-Mouhim A, Alam-Fahmy M, Tonin PN, Provencher DM, Mes-Masson AM. Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). Mol Carcinoge, 2007, 46(10): 872-885.

Funding

fundamental research funds for the central universities(JKJ01211515)